Glaukos Corp (GKOS) plunged 11.67% in the pre-market trading session on Friday, following the company's wider-than-expected net loss for the fourth quarter of 2024.

The medical technology firm reported a net loss of $22.2 million for the quarter, larger than the Wall Street estimate of a $20.8 million loss, according to data compiled by LSEG. While Glaukos posted revenue of $105.5 million, slightly above expectations of $100.7 million, the larger-than-anticipated loss appears to have spooked investors.

For the full year 2025, Glaukos forecasted sales in the range of $475 million to $485 million, compared to the consensus estimate of $479.8 million. The company's lead product is the iStent inject W, a device used to treat glaucoma, an eye condition that damages the optic nerve.